Join Dr. Orlowski as he explains the major toxicities associated with the daratumumab, lenalidomide, and dexamethasone regimen, and how to manage these adverse events.

Join Dr. McCarthy as he discusses which patients are likely to have a very fulminant or aggressive relapse, and how to risk-stratify these patients from diagnosis to prognosis.

Join Dr. Nooka as he explains how to manage patients who are experiencing adverse events with the two approved monoclonal antibodies, elotuzumab and daratumumab.

Join Dr. Nooka as he explains how to manage a patient who is experiencing adverse events with the only approved HDAC inhibitor, panobinostat.

Join Dr. Nooka as he explains how to manage patients who are experiencing adverse events with the three approved proteasome inhibitors, carfilzomib, bortezomib, and ixazomib.

Join Dr. Nooka as he explains how to manage a patient who is experiencing adverse events with immunomodulatory agents.

Dr. Philip McCarthy discusses which patients are transplant-eligible and what factors may limit their options.

Dr. Nooka discusses the crucial steps in identifying if your myeloma patient with cardiac history should receive carfilzomib and if so, when.

Join Dr. Usmani as he recommends the steps community oncologists should take to differentiate between, and provide ideal follow-up to, MGUS and smoldering MM patients.

Join Dr. Orlowski as he explains when to use daratumumab-lenalidomide-dexamethasone versus daratumumab-bortezomib-dexamethasone in clinical practice with multiple myeloma patients.